<DOC>
	<DOC>NCT01791855</DOC>
	<brief_summary>Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment. This study will investigate the effect of the drug in subjects with varying degrees of renal impairment. Pharmacokinetics, safety and toleration will be assessed.</brief_summary>
	<brief_title>PF-04634817 Renal Impairment Study</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Male or female (non child bearing potential aged 1875 years Documented renal impairment (mild, moderate or severe using CockcroftGault equation) or matched healthy volunteers (age, weight and gender) Subjects with acute renal failure Subjects receiving, or likely to receive, CYP450 3A4 inhibitors Abnormal ECG at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Subjects with Renal Impairment</keyword>
	<keyword>healthy</keyword>
</DOC>